Swedencare AB (publ) (STO:SECARE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 3.42B -39.3% |
| Revenue (ttm) | 2.72B +4.8% |
| Net Income | 80.10M +23.6% |
| EPS | 0.50 +22.2% |
| Shares Out | 159.84M |
| PE Ratio | 43.01 |
| Forward PE | 17.89 |
| Dividend | 0.28 (1.31%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 41,569 |
| Open | 21.35 |
| Previous Close | 21.40 |
| Day's Range | 21.35 - 21.65 |
| 52-Week Range | 21.15 - 42.00 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 39.50 (+82.87%) |
| Earnings Date | Jul 22, 2026 |
About Swedencare AB
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in North America, Europe, and internationally. The company offers animal nutritional supplements, treats, and grooming products for dogs under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and suppo... [Read more]
Financial Performance
In 2025, Swedencare AB's revenue was 2.69 billion, an increase of 6.13% compared to the previous year's 2.54 billion. Earnings were 55.50 million, a decrease of -43.88%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SECARE stock is "Buy." The 12-month stock price target is kr 39.50, which is an increase of 82.87% from the latest price.
News
Swedencare AB Earnings Call Transcript: Q2 2026
Q2 delivered resilient growth and strong cash generation, with Europe and Production segments outperforming and North America lagging due to delayed launches. Gross margin hit a record 61%, and profitability is expected to improve in H2 as investments normalize and delayed orders are fulfilled.
Swedencare AB Quarterly report: Q2 2026
Swedencare AB has published its Q2 2026 quarterly earnings report on July 22, 2026.
Swedencare AB Slides: Q2 2026
Swedencare AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 22, 2026.
Swedencare AB Transcript: Pre-close call
Strong double-digit organic growth and stable margins are expected, with Amazon-related issues set to normalize by early Q3. Board changes and strategic market expansions are underway, while the U.S. distributor merger presents ongoing operational challenges.
Swedencare AB Transcript: CMD 2026
Strong organic and M&A-driven growth is supported by expanded manufacturing, digital channels, and product innovation. Financial targets focus on double-digit organic growth, margin improvement, and disciplined capital allocation, while sustainability and employee engagement remain core priorities.
Swedencare AB Slides: FY 2026
Swedencare AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 2, 2026.
Swedencare AB Earnings Call Transcript: Q1 2026
Double-digit organic growth and record gross margin were achieved, driven by strong European and online sales, while North America stabilized and production segments rebounded. Major new contracts, product launches, and operational efficiencies support a positive outlook for 2026.
Swedencare AB Quarterly report: Q1 2026
Swedencare AB has published its Q1 2026 quarterly earnings report on April 23, 2026.
Swedencare AB Slides: Q1 2026
Swedencare AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Swedencare AB Transcript: Pre-close call
Stable demand and improved operational efficiency are driving higher margins and profitability, with strong growth in North America, Europe, and contract manufacturing. Walmart and Amazon channels show positive trends, and cost headwinds remain limited.
Swedencare AB Slides: Pre-close call
Swedencare AB has posted slides in relation to its latest quarterly earnings report, which was published on March 20, 2026.
Swedencare AB Earnings Call Transcript: Q4 2025
Q4 2025 saw strong organic growth but disappointing profitability due to one-off costs, marketing overspend, and inventory write-offs. Improved cost controls, new product launches, and a focus on pharma and online channels are expected to drive margin recovery and growth in 2026.
Swedencare AB Annual report: Q4 2025
Swedencare AB has published its Q4 2025 annual report on February 12, 2026.
Swedencare AB Quarterly report: Q4 2025
Swedencare AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Swedencare AB Slides: Q4 2025
Swedencare AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
SwedenCare downgraded to Hold from Buy at Nordea
Nordea downgraded SwedenCare (SWDCF) to Hold from Buy.
Swedencare AB Slides: SEB Nordic Seminar presentation
Swedencare AB has posted slides in relation to its latest quarterly earnings report, which was published on January 7, 2026.
Swedencare AB Earnings Call Transcript: Q3 2025
Record Q3 revenue and EBITDA were achieved, driven by strong growth in North America and Europe, major US retail expansion, and robust online sales. Outlook remains positive with double-digit growth and margin improvement expected, despite some margin pressure from marketing investments.
Swedencare AB Quarterly report: Q3 2025
Swedencare AB has published its Q3 2025 quarterly earnings report on October 22, 2025.
Swedencare AB Slides: Q3 2025
Swedencare AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 22, 2025.